AVEO Pharmaceuticals (AVEO) Peer Comparison
$15.00
$0.00 (0.00%)As on 20-Jan-2023 09:30EDT
Market cap
$521 Mln
Revenue (TTM)
$68 Mln
P/E Ratio
--
P/B Ratio
18
Div. Yield
0 %
Edit
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
Market cap ($ Mln) |
521 | 1,219 | 300 | 8 |
Revenue ($ Mln) |
68 | -- | 20 | 2 |
Net Profit ($ Mln) |
-29.04 | -61.64 | -176.65 | -30.42 |
Net Margin (%) |
-42.56 | -8,110.13 | -1,287.59 | -1,755.34 |
RoE (%) |
-88.28 | -33.13 | -- | -184.49 |
Price to Earnings |
-- | -- | -- | -- |
Price-To-Book |
17.96 | 7.04 | 2.39 | 1.02 |
Income Statement ($ Mln)
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Operating Revenue
|
38.87 | 0.00 | 24.54 | 3.51 |
|
Cost of Revenue
|
4.74 | -- | 1.53 | 3.51 |
|
Gross Profit
|
34.14 | -- | 23.01 | -3.51 |
|
Operating Expenses
|
87.11 | 42.52 | 119.67 | 39.22 |
|
Operating Profit (EBIT)
|
-49.55 | -42.52 | -96.66 | -39.22 |
|
Other Income
|
0.26 | -0.10 | -0.27 | -- |
|
Profit before Tax
|
-53.34 | -42.31 | -100.66 | -39.48 |
|
Provision for Tax
|
-- | 0.00 | -- | -0.78 |
|
Profit after Tax (Net Income)
|
-53.34 | -42.31 | -100.66 | -40.25 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Consolidated Profit
|
-53.34 | -42.31 | -100.66 | -40.25 |
Liabilities ($ Mln)
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Shareholder's Funds
|
45.87 | 214.69 | 99.54 | 34.16 |
|
Minority Interest
|
-- | -- | -- | -- |
|
Non-Current Liabilities
|
40.74 | 0.00 | 94.28 | 0.50 |
|
Current Liabilities
|
18.73 | 10.09 | 28.80 | 6.47 |
|
Total Liabilities
|
105.34 | 224.79 | 222.62 | 1.39 |
Assets ($ Mln)
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Non-Current Assets
|
0.61 | 3.48 | 7.37 | -38.35 |
|
Current Assets
|
104.74 | 221.30 | 215.25 | 39.74 |
|
Total Assets
|
105.34 | 224.79 | 222.62 | 34.66 |
|
Total Debt*
|
14.14 | -- | 92.73 | 0.55 |
|
Net Current Assets
|
86.01 | 211.21 | 186.45 | 33.27 |
Cashflow ($ Mln)
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Cash From Operating Activities
|
-57.26 | -39.76 | -89.37 | -38.36 |
|
Cash Flow from Investing Activities
|
-16.87 | -129.27 | -1.49 | -0.01 |
|
Cash from Financing Activities
|
82.90 | 160.99 | 91.64 | 33.33 |
|
Net Cash Inflow / Outflow
|
8.78 | -8.04 | 0.79 | 25.56 |
Ratios
Profitability Ratios
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
ROCE (%)
|
-111.94 | -58.00 | -53.03 | -110.12 |
|
ROE (%)
|
-131.44 | -58.00 | -70.34 | -110.96 |
|
ROA (%)
|
-61.93 | -26.14 | -47.87 | -170.51 |
|
EBIT Margin (%)
|
-- | -- | -- | -- |
|
Net Margin (%)
|
-136.32 | 42,738.38 | -414.76 | -1,148.15 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- |
Growth Ratios
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Revenue Growth (%)
|
5.46 | -- | -- | -0.05 |
|
EBIT Growth (%)
|
-- | -- | -- | -- |
|
Net Profit Growth (%)
|
-49.90 | -137.26 | -42.74 | -33.53 |
|
EPS Growth (%)
|
0.05 | 0.85 | -0.41 | 0.05 |
|
Book Value Growth (%)
|
-- | -- | -- | -- |
Valuation Ratios
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Price / Earnings
|
-2.90 | -8.97 | -4.75 | -2.96 |
|
Price / Book Value
|
3.37 | 1.77 | 4.80 | 3.49 |
|
Dividend Yield (%)
|
-- | -- | -- | -- |
|
EV/EBITDA
|
-1.18 | -3.86 | -3.90 | -2.01 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- |
Solvency Ratios
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Debt to Equity
|
0.40 | -- | 0.93 | 0.01 |
|
Short term debt to equity ratio
|
0.00 | -- | 0.01 | -- |
|
Current Ratio
|
5.59 | 21.93 | 7.47 | 6.14 |
|
Quick Ratio
|
5.50 | -- | 7.26 | -- |
|
Interest Coverage
|
-12.25 | -133.74 | -25.96 | -157.81 |
Operating Efficiency Ratios
| AVEO Pharmaceuticals (AVEO) | Imago Biosciences Inc (IMGO) | Oyster Point Pharma (OYST) | Ayala Pharmaceuticals Inc (AYLA) | |
|---|---|---|---|---|
|
Debtors to sales (%)
|
25.24 | -- | 27.12 | 0.00 |
|
Asset Turnover
|
0.45 | 0.00 | 0.12 | 0.15 |
|
Receivable days
|
51.71 | -- | 99.07 | 35.47 |
|
Inventory Days
|
127.69 | -- | 1,457.65 | -- |
|
Payable days
|
234.86 | -- | 1,050.84 | 361.50 |
|
Cash Conversion Cycle
|
-55.46 | -- | 505.88 | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
